CalciMedica, a clinical-stage biotechnology company developing CRAC inhibitors for the treatment of inflammatory diseases, announced results from their Phase 2 randomized, controlled, open-label clinical trial evaluating the CRAC inhibitor Auxora™ (also known as CM4620-IE) for the treatment of severe COVID-19 pneumonia.
Auxora™, when combined with standard therapy, improved outcomes in patients with severe COVID-19 pneumonia showing faster recovery and reduced use of invasive mechanical ventilation and death as compared to standard therapy alone. Auxora also showed a favorable safety profile.
CalciMedica plans to move to a randomized, blinded, placebo-controlled study of Auxora™ in the coming weeks.
Photo by CDC on Unsplash